BRAF and lung carcinoma: Moreover, in a Kras (G12V)/Braf (D631A)‐driven lung cancer model, the ablation of the wild‐type Braf allele further increased mitogen‐activated protein kinase (MAPK) signaling, leading to oncogenic toxicity and preventing the development of adenocarcinoma [5].